• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by PepGen Inc.

    4/25/25 8:01:56 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PEPG alert in real time by email
    DEFA14A 1 defa14a_04.25.2025.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

    Definitive Proxy Statement

     

     

    ☒

    Definitive Additional Materials

     

     

    ☐

    Soliciting Material under §240.14a-12

    PEPGEN INC.

    (Exact name of registrant as specified in its charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

     

    ☐

    Fee paid previously with preliminary materials

     

     

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     


    img162228255_0.jpg

    Logo PepGen TM C/OTABULATOR,P.O.BOX 80l6,CARY, NC27512-9903 Your vote matters! PepGen Inc. Annual Meeting of Stockholders Wednesday, June 4, 2025 12:00 PM, Eastern Day1ight Time Annual meeting to be held virtually via the internet – please visit \WWW.proxydocs.com/PEPG for more details. You must register to attend or participate in the annual meeting online at www.proxydocs.com/PEPGprior to the commencement of the annual meeting. For a convenient way to view proxy materials, VOTE. and obtain directions to attend the meeting go to www.proxydocs.com/PEPG To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares, We encourage you to access and review all of the important information contained in the proxy materials available on the Internet or by mail before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If You want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 23, 2025. SEEREVERSE FOR FULL AGENDA Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be Held on June 4, 2025 For Stockholders of record as of April 8, 2025 To order paper materials, use one of the following methods. Internet: www.investorelections.com/PEPG Call: 1-866-648-8133 Email: [email protected]* If requesting material by e-mail, please send s blank e-mail with the 12 digit controlnumber (located above) in the subject line. No other requests, instructions or other in queries should be included with your e-mail requesting material.your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright C 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


     

    img162228255_1.jpg

    Logo PepGen TM PepGen Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 PROPOSAL 1. To elect three Class III directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. 1 .01 Mitchell. Finer 1.02 Heidi Henson 1.03 Laurie B. Keating 2. To ratfy the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31. 2025. To transact any other business property brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting. Note: such other matters that may property come before the meeting or any adjournment or any postponement thereof will be voted by the persons named as proxies in their discretion.


    Get the next $PEPG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PEPG

    DatePrice TargetRatingAnalyst
    12/16/2024$3.00Neutral → Underperform
    BofA Securities
    7/31/2024$12.00Buy → Neutral
    BofA Securities
    12/21/2022$26.00Buy
    H.C. Wainwright
    More analyst ratings

    $PEPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PepGen downgraded by BofA Securities with a new price target

    BofA Securities downgraded PepGen from Neutral to Underperform and set a new price target of $3.00

    12/16/24 12:07:01 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen downgraded by BofA Securities with a new price target

    BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00

    7/31/24 11:28:59 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on PepGen with a new price target

    H.C. Wainwright initiated coverage of PepGen with a rating of Buy and set a new price target of $26.00

    12/21/22 9:28:36 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

    – Last patient dosed in 15 mg/kg cohort of FREEDOM-DM1; on track to report topline data from study in early Q4 2025 – – FREEDOM to conclude with the 15 mg/kg cohort based on splicing and safety data observed to date; clinical sites will begin transitioning to the Phase 2 multiple ascending dose study, FREEDOM2-DM1 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2025. "This quarter, we made further progress in the develo

    8/7/25 8:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

    – PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs – – PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild – – DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies, today announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) patients amenable

    5/28/25 4:05:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

    5/20/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Head of R&D Streck Paul bought $10,393 worth of shares (8,375 units at $1.24), increasing direct ownership by 43% to 27,805 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    6/2/25 5:03:19 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Mcarthur James G bought $13,550 worth of shares (10,000 units at $1.35), increasing direct ownership by 10% to 113,913 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    4/22/25 7:01:12 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Mcarthur James G bought $47,725 worth of shares (41,500 units at $1.15), increasing direct ownership by 66% to 103,913 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    4/9/25 7:40:15 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.

    SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)

    8/13/25 9:02:13 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PepGen Inc. (0001835597) (Filer)

    8/7/25 8:02:23 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by PepGen Inc.

    10-Q - PepGen Inc. (0001835597) (Filer)

    8/7/25 8:00:21 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Ra Capital Management, L.P.

    4 - PepGen Inc. (0001835597) (Issuer)

    6/6/25 8:43:35 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mayer Howard

    4 - PepGen Inc. (0001835597) (Issuer)

    6/6/25 6:56:13 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Henson Heidi

    4 - PepGen Inc. (0001835597) (Issuer)

    6/6/25 6:54:26 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Leadership Updates

    Live Leadership Updates

    View All

    PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

    5/20/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Announces Appointment of Two New Directors to its Board

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company. "We are thrilled to welcome Lisa and Mitch to our Board of Directors," said James McArthur, PhD, President and CEO of PepGen. "Lisa's proven ability to scale manufacturing for mid- to late-stage clinical trials and guide clinical-stage companies

    3/31/25 4:05:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization. "We are very pleased that Paul is joining PepGen at such an important time for the Company," said James McArthur, Ph.D., President and CEO of PepGen. "Throughout his career, Paul has served in leadership roles across both l

    8/20/24 8:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Financials

    Live finance-specific insights

    View All

    PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

    – Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today at 8:00 a.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). "These results far exceeded our expectations for splicing correctio

    2/24/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

    – PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation

    7/30/24 4:02:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call

    BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived

    3/16/23 8:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PepGen Inc.

    SC 13G/A - PepGen Inc. (0001835597) (Subject)

    11/14/24 4:31:29 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by PepGen Inc.

    SC 13G - PepGen Inc. (0001835597) (Subject)

    11/14/24 11:10:10 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PepGen Inc.

    SC 13G/A - PepGen Inc. (0001835597) (Subject)

    11/12/24 8:57:04 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care